In the general population, myelodysplastic syndromes (MDS) occurs in 5 per 100,000 people. However, among individuals older than age 70, the incidence is between 22 and 45 per 100,000. Managing MDS is complicated by the generally advanced age of the patients (median ages range from 65 to 70 years old), attendant nonhematologic comorbidities, and the older patients' relative inability to tolerate certain intensive forms of therapy. These guidelines extensively evaluate reviewed, risk-based data and indicate useful approaches for managing MDS.
For the most recent version of the guidelines, please visit NCCN.org